AI assistant
Oric Pharmaceuticals, Inc. — Director's Dealing 2021
May 25, 2021
32131_dirs_2021-05-24_1834ce4b-420d-4fce-96b1-2c8ea32648c5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-05-20
Reporting Person: Chacko Jacob (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-20 | Common Stock | S | 2468 | $25.0664 | Disposed | 27934 | Direct |
| 2021-05-21 | Common Stock | S | 4790 | $25.1958 | Disposed | 23144 | Direct |
| 2021-05-24 | Common Stock | S | 12 | $25.00 | Disposed | 23132 | Direct |
Footnotes
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Represents the weighted average share price of an aggregate total of 2,468 shares sold in the price range of $25.00 to $25.14 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 4,790 shares sold in the price range of $25.00 to $25.37 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.